Epidemiology and Prevention of Hepatitis A in Travelers
Article first published online: 29 JUL 2013
© 2013 International Society of Travel Medicine
Journal of Travel Medicine
Volume 20, Issue 6, pages 394–399, November/December 2013
How to Cite
Wu, D. and Guo, C.-Y. (2013), Epidemiology and Prevention of Hepatitis A in Travelers. Journal of Travel Medicine, 20: 394–399. doi: 10.1111/jtm.12058
- Issue published online: 24 OCT 2013
- Article first published online: 29 JUL 2013
- Manuscript Accepted: 14 JUN 2013
- Manuscript Revised: 11 JUN 2013
- Manuscript Received: 7 APR 2013
- National Natural Science Foundation of China. Grant Numbers: 81270515, 81101579, 81072005, 81172312
- Shanghai Science and Technology Foundation. Grant Number: 11430702400
- Chinese Foundation for Hepatitis Prevention and Control the WBN Research Foundation. Grant Number: 20100021
- Shanghai Municipal Health Bureau Foundation. Grant Numbers: 2011287, 2012107
Hepatitis A is the second most common vaccine-preventable travel-associated infectious disease and hepatitis A virus (HAV) is the most common cause of viral hepatitis. The incidence of infection is closely related to sanitary conditions and the level of economic development.
We evaluated HAV incidence, infection-related risk factors, and HAV vaccination rates in international travelers through retrospective analyses using major databases, such as CENTRAL, MEDLINE, EMBASE, and the current literature describing epidemiological data for HAV infection in recent years.
Results and Conclusions
We found that the incidence of HAV infection in developed countries is very low. As international travel increases, the incidence of hepatitis A among travelers remains high and likely leads to regional outbreaks. Travelers should visit the Centers for Disease Control and Prevention website or Infectious Disease Prevention Center of their countries to learn about the incidence of infectious diseases associated with their destination before going abroad to determine if they should be vaccinated.